HALO Halozyme Therapeutics, Inc.

11.39
+0  (0%)
Previous Close 11.39
Open 11.81
Price To book 0.00
Market Cap 1.46B
Shares 128,154,000
Volume 2,193,344
Short Ratio 15.05
Av. Daily Volume 1,973,210

SEC filingsSee all SEC filings

  1. 8-K - Current report 17519276
  2. 8-K - Current report 17517641
  3. 8-K - Current report 17508685
  4. 8-K - Current report 162059006
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978162

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA June 26, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 trials to be initiated in 2017.
Tecentriq and PEGPH20
Pancreatic and gastric cancers
Phase 1/2 initiated July 2016
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Approved Sept 12 2014
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Phase 2 data released January 5, 2017.
PEGPH20
Pancreatic cancer
Phase 1b enrolment resumed July 2016 under revised protocol
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Phase 2 topline data released 1Q 2014
HTI-501
Celluoite

Latest News

  1. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 16, 2017
  2. Halozyme Estimates 2017 Revenue of $115M to $130M
  3. Why trader is selling Halozyme calls
  4. Here's Why Halozyme Therapeutics Fell as Much as 11.1% Today
  5. HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  6. Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
  7. HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
  8. Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference
  9. Can the Rally in Halozyme (HALO) Shares Continue?
  10. Biotech Industry Off to a Strong Start in 2017 Latest Reports on Halozyme Therapeutics and Geron
  11. ETFs with exposure to Halozyme Therapeutics, Inc. : January 6, 2017
  12. Why Halozyme Therapeutics, Inc Fell 40.6% in 2016
  13. Company News for January 06, 2017
  14. Halozyme Pancreatic Cancer Drug Succeeds in Trial
  15. Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%
  16. Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
  17. Halozyme Therapeutics downgraded by Citigroup
  18. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : January 6, 2017
  19. Constellation Brands, Halozyme Therapeutics: Jim Cramer's Top Takeaways
  20. Why Barrick Gold, Halozyme Therapeutics, and CEB Jumped Today
  21. 3 ideas to improve waiting for your trades
  22. Macy's and Toyota skid; Sears jumps
  23. Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
  24. Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints
  25. Halozyme Reports Third Quarter 2016 Financial Results
  26. FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
  27. Halozyme To Host Third Quarter 2016 Financial Results Conference Call
  28. PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients
  29. Halozyme Names Mark J. Gergen As Chief Operating Officer
  30. Halozyme Reports Second Quarter 2016 Financial Results
  31. Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20
  32. Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
  33. Halozyme To Host Second Quarter 2016 Financial Results Conference Call
  34. Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
  35. Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
  36. Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
  37. Halozyme Reports First Quarter 2016 Financial Results
  38. Halozyme to Host First Quarter 2016 Financial Results Conference Call
  39. Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
  40. Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing
  41. Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology
  42. Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer

SEC Filings

  1. 8-K - Current report 17519276
  2. 8-K - Current report 17517641
  3. 8-K - Current report 17508685
  4. 8-K - Current report 162059006
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978162
  6. 8-K - Current report 161978123
  7. 8-K - Current report 161866410
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161817974
  9. 8-K - Current report 161817930
  10. CT ORDER - Confidential treatment order 161712360